摘要
目的观察养心氏对气虚血瘀型冠状动脉粥样硬化性心脏病心绞痛患者内皮素(ET)、一氧化氮(NO)、C-反应蛋白(CRP)的影响。方法78例患者随机分为2组,治疗组(40例)口服养心氏片,每次4粒,每日3次;对照组(38例)口服单硝酸异山梨酯,每次1片,每日3次。服药前后记录ET、NO、CRP、心绞痛症状及全身症状改善情况。两组均2周为1个疗程,4个疗程后统计疗效。结果治疗组患者ET、NO、CRP均明显改善,ET由(67.47±15.72)pg/mL改善为(37.97±7.82)pg/mL,NO由(78.24±13.81)μmol/mL改善为(96.25±12.72)μmol/mL,CRP由(5.31±2.02)mg/L改善为(3.42±2.17)mg/L,与对照组相比均有显著性差异(P<0.05);心绞痛总有效率为90%,与对照组相比无显著性差异(P>0.05);症状疗效总有效率为95%,与对照组相比有显著性差异(P<0.01)。结论养心氏治疗气虚血瘀型冠状动脉粥样硬化性心脏病心绞痛疗效明显,能明显降低ET、NO、CRP,且无任何毒副作用。
Objective To observe the influences of Yangxinshi pill on ET, NO, CRP in patients with angina pectoris belonging to manifestation of Qi-deficiency and blood stagnation. Methods 78 patients with angina pectoris were randomly divided into two groups. 40 patients in treatment group were treated with Yangxinshi pill, 4 pills once, three times a day 8 weeks. 38 patients in control group were treated with isosorbide mononitrate 8 weeks. The symptoms and the ET, NO, CRP level before and after treatment were recorded. Results Obvious drop of ET, NO, CRP were observed after treatment in the treatment group. The level of ET was reduced from （67.47± 15.72）pg/mL to （37.97±7.82） pg/mL. The level of NO was increased from （78.24± 13.81）μmol/mL to （96.25 ±12.72）μmol/mL. The level of CRP was reduced from （5.31± 2.02）mg/L to （3.42±2.17） mg/L. There was a significant difference between the two drugs （P〈0.05）. The total efficacy rate in improving angina pectoris was 90%. There was no difference between the two drugs （P〉0.05）. The total efficacy rate in improving symptom was 95%. There was a significant difference between the two drugs （P〈0.01）. Conclusion Yangxinshi pill is useful to treat angina pectoris and obviously improving blood ET, NO, CRP without any side effect.
出处
《中国中医药信息杂志》
CAS
CSCD
2006年第12期14-16,共3页
Chinese Journal of Information on Traditional Chinese Medicine
